Navigation Links
European Hospital Anticoagulant Market Dominated by Sanofi-Aventis's Clexane

MALVERN, Pa., Sept. 28 /PRNewswire/ -- Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that more than half of all European inpatients who receive anticoagulants during their hospital stay are administered Sanofi-Aventis's Clexane (marketed as Lovenox in the U.S. and France).

The new audit entitled The European Hospital Anticoagulant Market Guide is a comprehensive source for anticoagulant use in European hospitals. Released quarterly, the audit contains detailed clinical data from thousands of hospitalized patients receiving anticoagulants. Survey results are projected to the national level for France, Germany, Italy, Spain and the United Kingdom.

The audit also reveals that surgical venous thromboembolism (VTE) primary prophylaxis accounts for the largest share of inpatient anticoagulant use at 48 percent of all inpatients. However, non-surgical VTE and stroke prophylaxis remains a key area of growth opportunity for companies marketing and developing anticoagulant agents.

The European Hospital Anticoagulant Market Guide is designed to help biopharmaceutical companies quantify targeted patient segments, better understand treatment practices and customers, size commercial opportunity and formulate clinical development strategy.

Besides Clexane, Boehringer Ingelheim's Pradaxa, Bayer's Xarelto and all other anticoagulants used in European hospitals are tracked in this audit.

About AMR

AMR ( serves the market intelligence needs of the pharmaceutical and diagnostic imaging industries. Research includes clinical inpatient databases that directly link anti-infective drug with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits. AMR is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

SOURCE Arlington Medical Resources
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. For Multiple Myeloma Treatment, More Surveyed European Clinicians Consider the Combination of Immunomodulatory Agents and Proteasome Inhibitors Promising With Respect to Efficacy Than Any Other Drug Regimen Combinations
2. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
3. Metabolic Solutions Development Company to Present Research Findings to European Association for the Study of Diabetes
4. InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS)
5. Tibotec Pharmaceuticals Seeks European Marketing Authorization for Investigational Once-Daily HIV Treatment TMC278
6. European Interspinous Process Decompression Device Market Will Grow Nominally at 1.2% over the Next Five Years
7. For Treatment of Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia, 41 Percent of Surveyed European Hematologist-Oncologists Say MabTheras Favorable Efficacy Profile is the Most Significant Driver of Their Use of This Agent
8. Mindray Medical to Present at the Goldman Sachs 7th Annual European Medtech and Healthcare Services Conference
9. Sunridge Schedules European Meetings
10. European Patent Office Upholds GlideScope® Video Laryngoscope Patent
11. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
Post Your Comments:
(Date:11/30/2015)... HANOVER, N.J. , Nov. 30, 2015  Novartis ... portfolio at the 57 th American Society of ... leukemias, lymphomas and myelomas as well as supportive care, ... in addition to personalized cell therapies. The ASH Annual ... Orlando, Florida . Novartis Oncology . ...
(Date:11/30/2015)... and BOSTON , November 30, 2015 ... develop potential new medicines directed at up to 10 ... --> PFE ) to research and develop ... protein-coupled receptor (GPCR) targets across multiple therapeutic areas. ... drug discovery and development company and wholly-owned subsidiary of ...
(Date:11/30/2015)... 2015 Elbit Imaging Ltd. (TASE, ... today that it was informed by InSightec Ltd. ("InSightec"), that ... has approved its Exablate Neuro system to treat movement, ... --> Insightec,s Exablate Neuro platform is transforming ... two technologies: Focused Ultrasound, which is used to lesion ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... Holcomb ... the leading plastic surgery practices in Florida, is proud to announce that Dr. ... surgical innovations giant Ethicon Inc., a Johnson & Johnson Company. , Ethicon is ...
(Date:11/30/2015)... ... November 30, 2015 , ... The successful filing of an Investigational New Drug ... so important to this key industry segment, Regis Technologies has decided to sponsor and ... 4th at 11am EST. , Federal law does not allow new drugs to cross ...
(Date:11/30/2015)... ... November 30, 2015 , ... Healthjump, Inc. ... Inc., a Healthcare IT consulting, development and support company. The purchase will expand ... available within DataTrade to extend the services currently provided by Healthjump. ...
(Date:11/30/2015)... ... November 30, 2015 , ... GKhair & Tibolli team members and artists were ... held on November 8th and 9th at the Puerto Rico Convention Center, San Juan ... beauticians and top of the line fashion journalists. The San Juan Beauty Show carries ...
(Date:11/30/2015)... ... 2015 , ... Innovaacom, a leading provider of medical education ... of educational needs for pharmacists worldwide. The poll of pharmacists in Europe, Asia, ... online and face-to-face education for pharmacists who are fast becoming the new “gatekeepers” ...
Breaking Medicine News(10 mins):